These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12142637)

  • 41. Effects of age and sex on olanzapine plasma concentrations.
    Weiss U; Marksteiner J; Kemmler G; Saria A; Aichhorn W
    J Clin Psychopharmacol; 2005 Dec; 25(6):570-4. PubMed ID: 16282840
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variables associated with high olanzapine dosing in a state hospital.
    Botts S; Littrell R; de Leon J
    J Clin Psychiatry; 2004 Aug; 65(8):1138-43. PubMed ID: 15323601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Analysis of olanzapine in human plasma with reversed-phase high performance liquid chromatography].
    Xiao H; Xie SP; Fan JX; Yao H; Han G
    Se Pu; 2001 May; 19(3):281-2. PubMed ID: 12541820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute dystonia caused by low dosage of olanzapine.
    Alevizos B; Papageorgiou C; Christodoulou GN
    J Neuropsychiatry Clin Neurosci; 2003; 15(2):241. PubMed ID: 12724469
    [No Abstract]   [Full Text] [Related]  

  • 45. Olanzapine: interaction study with imipramine.
    Callaghan JT; Cerimele BJ; Kassahun KJ; Nyhart EH; Hoyes-Beehler PJ; Kondraske GV
    J Clin Pharmacol; 1997 Oct; 37(10):971-8. PubMed ID: 9505989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
    Reis M; Lundmark J; Björk H; Bengtsson F
    Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration.
    Markowitz JS; DeVane CL
    J Clin Psychopharmacol; 1999 Jun; 19(3):289-91. PubMed ID: 10350045
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
    Miller DS; Yatham LN; Lam RW
    J Clin Psychiatry; 2001 Dec; 62(12):975-80. PubMed ID: 11780879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Olanzapine-induced manic-like syndrome.
    Lindenmayer JP; Klebanov R
    J Clin Psychiatry; 1998 Jun; 59(6):318-9. PubMed ID: 9671347
    [No Abstract]   [Full Text] [Related]  

  • 50. Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.
    Söderberg MM; Haslemo T; Molden E; Dahl ML
    Pharmacogenomics J; 2013 Dec; 13(6):544-50. PubMed ID: 23147717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
    Gómez JC; Sacristán JA; Hernández J; Breier A; Ruiz Carrasco P; Antón Saiz C; Fontova Carbonell E
    J Clin Psychiatry; 2000 May; 61(5):335-43. PubMed ID: 10847307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. D2 receptor occupancy under recommended and high doses of olanzapine.
    Harvey EJ; Taylor DM; Flanagan RJ
    J Psychopharmacol; 2001 Sep; 15(3):213-4. PubMed ID: 11565632
    [No Abstract]   [Full Text] [Related]  

  • 53. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
    Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
    J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
    Crawford AM; Beasley CM; Tollefson GD
    Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide.
    Onofrj M; Paci C; D'Andreamatteo G; Toma L
    J Neurol; 2000 Jun; 247(6):443-6. PubMed ID: 10929273
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuroleptic malignant syndrome and low-dose olanzapine.
    Suh H; Bronson B; Martin R
    Am J Psychiatry; 2003 Apr; 160(4):796. PubMed ID: 12668376
    [No Abstract]   [Full Text] [Related]  

  • 57. A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure.
    Raggi MA; Casamenti G; Mandrioli R; Volterra V
    J Chromatogr B Biomed Sci Appl; 2001 Jan; 750(1):137-46. PubMed ID: 11204214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Olanzapine overdose with serum concentrations.
    Cohen LG; Fatalo A; Thompson BT; Di Centes Bergeron G; Flood JG; Poupolo PR
    Ann Emerg Med; 1999 Aug; 34(2):275-8. PubMed ID: 10424935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of smoking cigarettes, age, and sex with serum concentrations of olanzapine in patients with schizophrenia.
    Horvat M; Kadija M; Ščavničar A; Živković M; Šagud M; Lovrić M
    Biochem Med (Zagreb); 2023 Oct; 33(3):030702. PubMed ID: 37841771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Behavioral characteristics of olanzapine: an atypical neuroleptic.
    Fu Y; Zhu ZT; Chen LJ; Yu LP; Jin GZ
    Acta Pharmacol Sin; 2000 Apr; 21(4):329-34. PubMed ID: 11324461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.